Transposagen Biopharmaceuticals, Inc. Sustainability Profile
Transposagen Biopharmaceuticals, Inc., headquartered in the United States, is a pioneering entity in the biopharmaceutical industry, specialising in gene editing and cell line development. Founded in 2006, the company has established itself as a leader in providing innovative solutions for research and therapeutic applications, particularly through its proprietary technologies such as the Transposagen Gene Editing System. With a focus on creating custom cell lines and genetically modified organisms, Transposagen's unique offerings cater to the needs of academic, pharmaceutical, and biotechnology sectors. The company has achieved significant milestones, including collaborations with major research institutions and contributions to advancements in gene therapy. Renowned for its commitment to quality and innovation, Transposagen continues to solidify its market position as a trusted partner in the evolving landscape of biopharmaceutical research and development.
DitchCarbon Score
How does Transposagen Biopharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Transposagen Biopharmaceuticals, Inc.'s score of 67 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Transposagen Biopharmaceuticals, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Lonza Group AG, which influences its climate commitments and initiatives. Transposagen's climate strategy is informed by the sustainability targets set by Lonza Group AG, which operates at a cascade level of 2. While specific reduction targets from the Science Based Targets initiative (SBTi) or other frameworks are not detailed for Transposagen, the overarching commitments from Lonza Group AG may guide their environmental policies. As a subsidiary, Transposagen is expected to align with Lonza's sustainability goals, which include industry-standard climate initiatives. However, without specific emissions data or reduction targets available for Transposagen, it is challenging to provide a detailed overview of their carbon footprint or climate commitments. In summary, while Transposagen Biopharmaceuticals, Inc. does not currently disclose emissions data or specific reduction targets, it is positioned within the sustainability framework established by its parent company, Lonza Group AG.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 574,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 348,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Transposagen Biopharmaceuticals, Inc.'s Industry?
How Carbon Intensive is Transposagen Biopharmaceuticals, Inc.'s Location?
Transposagen Biopharmaceuticals, Inc.'s Scope 3 Categories Breakdown
Transposagen Biopharmaceuticals, Inc.'s Scope 3 emissions, which decreased by 3% last year and increased by approximately 2% since 2021, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 68% of Scope 3 emissions.
Top Scope 3 Categories
Transposagen Biopharmaceuticals, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Transposagen Biopharmaceuticals, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
